SCHEDULE 13G: Frazier Life Sciences Funds Disclose Significant Stake in Lexeo Therapeutics, Exceeding 9.9% Beneficial Ownership
Beneficial Ownership Report
Frazier Life Sciences and its affiliated funds have filed a Schedule 13G, revealing a collective beneficial ownership of up to 9.9% in Lexeo Therapeutics, Inc., primarily through direct shareholdings and exercisable warrants.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) beneficially own 3,730,419 shares of Lexeo Therapeutics Common Stock, representing 6.8% of the class.
- This ownership for Frazier Life Sciences Public Fund includes 3,073,467 directly held shares and 656,952 shares issuable from warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities beneficially own 818,607 shares, or 1.5% of the class, comprising 624,804 direct shares and 193,803 shares from exercisable warrants.
- Frazier Life Sciences X, L.P. and its related entities beneficially own 114,541 shares, or 0.2% of the class, consisting of 87,424 direct shares and 27,117 shares from exercisable warrants.
- Frazier Life Sciences XI, L.P. and its related entities beneficially own 304,989 shares, or 0.6% of the class, including 232,784 direct shares and 72,205 shares from exercisable warrants.
- Frazier Life Sciences XII, L.P. and its related entities beneficially own 532,256 shares, or 1.0% of the class, made up of 406,246 direct shares and 126,010 shares from exercisable warrants.
- James N. Topper and Patrick J. Heron each beneficially own 5,500,812 shares, representing 9.9% of the class, which includes the aggregate holdings across all Frazier Life Sciences funds mentioned.
- Albert Cha and James Brush each beneficially own 4,549,026 shares, representing 8.3% of the class, encompassing holdings from Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences Public Overage Fund, L.P.
- Daniel Estes beneficially owns 837,245 shares, representing 1.5% of the class, derived from holdings in Frazier Life Sciences XI, L.P. and Frazier Life Sciences XII, L.P.
- The percentages are calculated based on 33,196,997 shares of Lexeo Therapeutics Common Stock outstanding as of May 12, 2025, plus 20,790,120 shares sold in a public offering, and the respective exercisable warrants.
- The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of Lexeo Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the company's performance or outlook. The sentiment is neutral.
Future Outlook
NA
Industry Context
This filing reflects a significant investment by Frazier Life Sciences, a prominent life sciences investment firm, in Lexeo Therapeutics, a company operating in the biotechnology sector. Such substantial ownership by a specialized fund can signal confidence in the issuer's long-term prospects within the competitive biotech industry.
Stakeholder Impact
- Shareholders: The disclosure of significant beneficial ownership by institutional investors like Frazier Life Sciences can influence investor perception and potentially stock valuation, signaling institutional confidence or a strategic interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2017-07-31 | Date a Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC. |
| 2021-08-16 | Date a Power of Attorney for Albert Cha and James Brush was filed with the SEC. |
| 2022-04-18 | Date a Power of Attorney for Daniel Estes was filed with the SEC. |
| 2025-05-12 | Date as of which 33,196,997 shares of Lexeo Therapeutics' Common Stock were reported outstanding in the Issuer's Form 10-Q/A. |
| 2025-05-15 | Date Lexeo Therapeutics' Quarterly Report on Form 10-Q/A was filed with the SEC. |
| 2025-05-27 | Date Lexeo Therapeutics' Current Report on Form 8-K was filed with the SEC, detailing the sale of 20,790,120 shares in a public offering. |
| 2025-05-28 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-06-04 | Date of signing for the Joint Filing Agreement and the Schedule 13G. |
Keywords
Lexeo Therapeutics, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Fund, SEC Filing, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.